Scarica l'app Stockscreener
3.42
1.72%
-0.06
Dopo l'orario di chiusura:
3.38
-0.04
-1.17%
Precedente Chiudi:
$3.48
Aprire:
$3.48
Volume 24 ore:
328.62K
Relative Volume:
0.51
Capitalizzazione di mercato:
$311.17M
Reddito:
$114.70K
Utile/perdita netta:
$-26.49M
Rapporto P/E:
-1.3866
EPS:
-2.4665
Flusso di cassa netto:
$-53.17M
1 W Prestazione:
-8.06%
1M Prestazione:
-9.52%
6M Prestazione:
-16.59%
1 anno Prestazione:
+60.56%
Intervallo 1D:
$3.395
$3.53
Intervallo di 1 settimana:
$3.395
$3.75
Portata 52W:
$1.85
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Nome
Sab Biotherapeutics Inc
Settore
Industria
Telefono
305-845-2813
Indirizzo
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.42 | 316.63M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-02 | Iniziato | Rodman & Renshaw | Buy |
| 2025-12-19 | Iniziato | Guggenheim | Buy |
| 2025-09-17 | Iniziato | Leerink Partners | Outperform |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-10-09 | Iniziato | Craig Hallum | Buy |
| 2024-08-28 | Iniziato | Oppenheimer | Outperform |
| 2021-11-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
SAB BIO to Participate in Upcoming Investor Conferences - Yahoo Finance
SAB Biotherapeutics Inc. (SABS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SAB Biotherapeutics Inc. Warrant (SABSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
SAB (SABSW) Session: Moves 7.02% Down to $0.03 at the Close; Boundary Watch - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionCash Secured Put - vinanet.vn
SAB (SABSW) Latest: Falls 14.29% to $0.02 in the Current Update; Level Watch - vinanet.vn
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusHull Moving Average - dars.gov.et
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
S.D.-born biotech advances potential Type 1 diabetes therapy through global trial - SiouxFalls.Business
SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
SAB Biotherapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
SABS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Development CostsEarnings Miss Streak - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
SAB Biotherapeutics Warrant (SABSW) Jumps 40.85% to $0.02 Amid Renewed Speculative InterestHigh Reward Trades - vinanet.vn
SABSW Edges Higher in Thin Trading: Warrant Holds at $0.01Put Flow Alert - vinanet.vn
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS - TradingView
SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.900|Chg%:+0.050 - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):